Core Viewpoint - The company, Taimei Medical Technology (02576.HK), has submitted a filing to the China Securities Regulatory Commission (CSRC) for the implementation of full circulation of its H-shares, indicating a significant step towards enhancing its market presence and liquidity [1] Summary by Sections - H-share Conversion - The company has applied to convert a total of 363,186,467 shares of domestic shares held by certain shareholders into H-shares for listing on the Hong Kong Stock Exchange [1] - Regulatory Approval - The conversion of domestic shares into H-shares will occur once all necessary approvals and filings from regulatory bodies, including the CSRC and the Stock Exchange, are obtained and all applicable laws and regulations are met [1] - Shareholder Meeting Requirement - According to the company's articles of association, there is no need to convene a shareholders' meeting to approve the conversion and listing of the shares [1]
太美医疗科技(02576.HK)建议实施H股全流通